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Abstract
Background: Streptozocin (STZ) based chemotherapy is recommended for patients with metastatic pancreatic
neuroendocrine tumors (pNET). Temozolomide as mono- or combination therapy has been suggested to be a
promising alternative. However, the treatment is costly and not approved for the treatment of pNETs. Dacarbazine
(DTIC) shares the active metabolite with temozolomide and is broadly available at a low cost. The aim of this study was
a retrospective evaluation of the efficacy and tolerability of a lower dose DTIC-regimen in patients with progressive
advanced NETs.
Methods: We retrospectively analyzed 75 patients with NETs predominantly of pancreatic origin treated at our center
between 1998 and 2013. 650 mg/m2 of DTIC were administered intravenously over 60 min every 4 weeks.
Morphological response was assessed according to RECIST1.1 criteria. The median progression free survival (PFS) was
calculated using Kaplan-Meier and Cox regression methods, respectively. Univariate analyses of possible prognostic
markers were performed.
Results: The objective response rate (ORR) was 27 % for the entire cohort and 32 % in 50 pNET patients, respectively.
Stable disease (SD) was documented in 29 patients (39 %). Median PFS (mPFS) in patients receiving DTIC was 7 months
(3.9–10; 95 % confidence interval). Radiological and biochemical response were the only significant prognostic markers
for longer PFS in univariate analysis. Treatment was well tolerated. Nausea was the most common side effect (31 %),
only one case (1.3 %) of grade 3 toxicity (vomiting) occurred.
Conclusion: Low dose DTIC chemotherapy is an effective and well-tolerated treatment option in patients with
progressive well differentiated neuroendocrine neoplasms, especially of pancreatic origin.
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Background
With the advent of novel molecular targeted treatments
such as everolimus and sunitinib the therapeutic arma-
mentarium in metastatic neuroendocrine tumors (NET)
has broadened. Chemotherapy is still considered first
line treatment in specific patient subgroups such as pa-
tients with neuroendocrine carcinoma where platinum-
based chemotherapy is recommended [1]. The European
Neuroendocrine Tumor Society (ENETS) suggests using
a streptozocin-based chemotherapy as first line treat-
ment in metastatic pancreatic neuroendocrine tumors
(pNET) G1 and G2 with a high tumor burden or tumor-
related local symptoms [2] and as second line treatment
in progressive pNET. In recent years some small studies
reported promising results for the alkylating agent temo-
zolomide as single- or combination therapy. In a retro-
spective study first-line treatment of 30 patients with
pancreatic neuroendocrine tumors (pNET) with temozo-
lomide and capecitabine resulted in an impressive re-
sponse rate of 70 % and a 2 year survival rate of 92 %
[3]. Dacarbazine is an alkylating agent sharing the active
metabolite metozolomide with temozolomide. Different
regimens of dacarbazine have been used for more than
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three decades. Early reports included clinical and mor-
phological responses in patients with glucagonoma syn-
drome [4, 5]. The largest monotherapy study so far
comprised 50 patients with progressive pNET treated
with 850 mg/m2 dacarbazine every 4 weeks. The re-
sponse rate of this Eastern Cooperative Oncology Group
study was 33 %. Most responders had not received prior
chemotherapies [6]. This protocol was associated with
relevant toxicities including two deaths, 13 % grade 3
vomiting and 10 % grade 4 hematotoxicity. In another
large randomized trial of the Eastern Cooperative Oncol-
ogy Group dacarbazine as second line treatment in pa-
tients with carcinoid tumors resulted in a response rate
of only 8.2 % [7].
In this study we retrospectively investigated the effi-
cacy and safety of a modified, less dose intense dacarba-
zine treatment schedule comprising single intravenous
applications of 650 mg/m2 DTIC every 4 weeks in a co-
hort of 75 mostly pretreated patients with well differen-




We retrospectively evaluated 75 consecutive patients
with histologically confirmed well differentiated neuro-
endocrine neoplasms who were treated at our hospital
with dacarbazine between 1998 and 2013. All patients
had measurable disease according to the Response
Evaluation Criteria in Solid Tumors (RECIST 1.1). A
total of 40 male and 35 female patients with a median
age of 56 years (range 28–80) were treated. Patient char-
acteristics are summarized in Table 1.
For all but four patients dacarbazine represented at
least the second line of treatment, median number of
pretreatments was two (0–5). Thus the cohort is repre-
sentative for heavily pretreated patients (details of the
pretreatments are given as Additional file 1: Table S1).
Treatment and evaluation
DTIC treatment was initiated after documented tumor
progression. 650 mg/m2 of DTIC were administered
intravenously over 60 min every 4 weeks. All patients re-
ceived granisetron as antiemetic premedication.
Patients were restaged every 3 months using CT or
MRI-scans and by measuring serum chromogranin A
(CgA) levels. Biochemical response was defined as a
decrease of CgA of at least 30 %. Morphological re-
sponse was assessed according to RECIST1.1 criteria.
Side effects were collected from the medical files and
classified according to the common toxicity grading
system (Common Terminology Criteria for Adverse
Events Version 4.0).
Statistical analysis
The median progression free survival (PFS) was calcu-
lated using Kaplan-Meier and Cox regression methods,
respectively. Univariate analyses were performed. All
statistical calculations were performed using SPSS (IBM
SPSS Statistics). Differences were considered statistically
significant when the P value was less than 0.05. The pri-
mary endpoint was the objective response rate (ORR).
Secondary endpoints included progression free survival
(time from first dose of chemotherapy until documenta-




A median of eight courses of DTIC (range 3–46) were
administered. A biochemical response was observed in
19 of 39 patients (49 %) with elevated plasma CgA
Table 1 Summary of patient characteristics
Characteristic Number Percent
Age (years) median: 56 range: 27–78
< 60 49 65.3

















1 prior treatment 24 32
> 1 prior treatment 43 57
No pretreatment 4 5.3
No data available 4 5.3
Metastases
No metastases (locally advanced) 2 2.6
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before dacarbazine therapy. Median PFS (mPFS) in pa-
tients receiving DTIC was 7 months (3.9–10; 95 % confi-
dence interval). A partial remission (PR) could be
documented in 20/75 patients (27 %). Responding pa-
tients had well differentiated NETs of pancreatic (n =
16), intestinal (n = 1), bronchial (n = 2) and gastric (n =
1) origin. PR lasted a median of 24 months (95 % confi-
dence interval: 17.4–30.5). Stable disease was observed
in 29 patients (39 %):17 of pancreatic, one of colonic,
five of intestinal, three of bronchial, two of unknown
primary and one of thymic origin. Stable disease lasted a
median of 13 months (95 % CI: 11.3–14.8). Disease pro-
gression occurred in 26 patients (35 %).
The separate analysis of NENs of pancreatic origin
demonstrated a partial remission in 32 % (n = 16/50)
with a median progression free survival of 27 months
(95 % CI: 23.1–30.9). Stable disease was found in 17 pa-
tients (34 %) who had a median progression free survival
of 18 months (95 % CI: 13.7–22.3). Progressive disease
occurred in 17 patients (32 %) with pancreatic NEN. As
shown in Fig. 1, overall progression free survival was
10 months for pancreatic and 6 months for all non pan-
creatic NETs, this difference, however, was not statisti-
cally significant (p = 0.65).
A univariate analysis of potential prognostic markers for
PFS revealed that only radiologic and biochemical response
to DTIC were significant prognostic markers. Patients with
G1 tumors tended to have a longer PFS compared to pa-
tients with G2 tumors (p = 0.058). Differences in sex, age,
functional activity, site of primary and number of pretreat-
ments were not statistically significant (Table 2).
Toxicity
Chemotherapy related adverse effects were documented
in 43 patients of the entire study cohort (57.3 %) but
were usually mild with only one case of grade 3 toxicity
(vomiting, 1.3 %). The most common side effects were
nausea (n = 23 (31 %)) and vomiting (n = 13 (17 %)).
Transient elevations of liver enzymes were noted in 12
patients (15 %). Mild hematotoxicity was observed in
eight patients (10.7 %). Other side effects were diarrhea
(15 %), fatigue (5 %) and weight loss (3 %). Only two pa-
tients stopped DTIC due to intolerable side effects. De-
tailed information on chemotherapy related adverse
effects is given in Table 3.
Discussion
Streptozocin based chemotherapies have been the main-
stay of treatment of metastatic pNET since they were
Fig. 1 Kaplan-Meier survival curves for progression free survival of
pancreatic versus non-pancreatic NETs; mPFS: median progression
free survival. Overall progression free survival tended to be longer
for pancreatic (10 months) than for non pancreatic NETs (6 months)
without statistical significance (p = 0.65)
Table 2 Univariate analysis of possible prognostic factors for
progression free survival



































































*significant differences; CI confidence interval, FNA functional non active, FA
functional active, CTx chemotherapy, SSA somatostatin analogue, IFN interferon
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first described by Moertel in 1980 with response rates
up to 69 % [8]. These report rates have been questioned
by others [9] because of partial reliance on nonmorpho-
logic response criteria including clinical and biochemical
assessments. Nevertheless, the efficacy of streptozocin
(STZ) based therapies has been confirmed by several
groups [10–16] with documented response rates of 30–
40 % according to radiologic criteria. Thus, STZ-based
therapies have been recommended for the treatment of
metastatic pNET by all international guidelines. How-
ever, disadvantages of the STZ based protocols include
the need for a 5 days course and the risk of nephrotox-
icity (9 % in the Moertel group) that could preclude po-
tential second line therapies such as PRRT.
In this study, we report on the efficacy and tolerability
of low dose dacarbazine in a large single center cohort.
Dacarbazine (DTIC) is a well known agent that has
safely and efficiently been used for the treatment of ma-
lignant melanomas and glioblastomas for many years. In
NEN patients combination treatments of low doses of
DTIC (200 or 250 mg/m2) with 5-FU and epirubicin re-
sulted in response rates between 18 and 44 % [17–20].
In addition, some older studies used DTIC 250 mg/m2
in a 5 day treatment schedule [21–23], such as Altimari
and coworkers who demonstrated response rates of 50 %
in a small series of 14 patients.
Evidence for the efficacy of single dose DTIC monother-
apy is limited. Bukowski and coworkers investigated the
use of DTIC in a series of 56 patients with NENs of vari-
ous primaries at a dose of 650 and 850 mg/m2 showing re-
sponse rates of 20 % for the 850 mg/m2 dose and 13 % for
the 650 mg/m2 dose [24]. Ramanathan and coworkers re-
ported a response rate of 33 % in 50 patients with pancre-
atic NEN who received DTIC at a dose of 850 mg/m2.
The response rate was higher in treatment naïve patients
(50 %) compared to pretreated patients (14 %) [6]. Sun et
al. observed a response rate of only 8 % with DTIC
(250 mg/m2 d1-d5, every 4 weeks) after failure to STZ/5-
FU or STZ/Doxorubicin chemotherapy in patients with
advanced neuroendocrine tumors mainly of extrapancrea-
tic origin [7]. The interpretation of the results needs some
caution, since the cohorts show major differences. In all
but one study NENs of all origins were included which ex-
plains some of the lower response rates, since chemother-
apy is mostly effective in pNETs but not in midgut
tumors, an observation as well confirmed in our study.
Furthermore the studies differ in the number of patients
that were pretreated, the number of pretreatments and
other prognostic factors that could have influenced the
treatment outcome like grading or tumor load. However,
the majority of studies suggest that DTIC-based chemo-
therapy is active in well-differentiated NENs, though ques-
tions remain about the dosing schedule achieving the
highest efficacy at an acceptable toxicity.
In accordance with these previously reported results
we could clearly demonstrate in our retrospective study
that DTIC chemotherapy is effective in 75 patients with
well differentiated NEN, which represents the biggest
series reported so far. 66 % of the patients had a benefit
from DTIC chemotherapy documented by an overall
partial remission (PR) in 27 % and disease stabilization
(SD) in 39 % of the patients. As expected, efficacy varied
depending on the primary site of the tumor. It has to be
stressed that in our series all but four patients received
DTIC after disease progression to at least one prior
treatment which renders the response rate even more
remarkable. Median PFS in pNEN was 10 months and
thus comparable to the results of everolimus and suniti-
nib in progressive pNET patients. Remarkably, in pa-
tients with benefit we observed sustained response or
stabilization periods, lasting a median of 27 months in
patients with PR and 18 months for patients with SD.
These results are comparable or only slightly inferior to
those achieved with the established streptozocin based
protocols.
Efficacy in small bowel NENs which are known to be
less chemosensitive was low (PR 9 %), whereas four of
six bronchus carcinoids benefited from DTIC therapy
(PR 33 %, SD 33 %), suggesting that this regimen may
also be effective in other foregut NENs. In the same way
Ekeblad and coworkers included 13 bronchial carcinoids
in their study using temozolomide and found a response
rate of 31 % [25]. Since the number of patients with
NEN of this origin was low in both series, further studies
are needed to clarify the efficacy of temozolomide and
dacarbazine for bronchial NEN.
In contrast to previous reports primarily with more
dose intense DTIC schedules in our study DTIC demon-
strated a good safety profile. While in our study side
Table 3 Toxicity
Side effects n % Grade 1 Grade 2 Grade 3
Hematologic
Anemia 4 5 4 – –
Leukopenia 6 8 5 1 –
Thrombocytopenia 2 3 – 2 –
Gastrointestinal
Nausea 23 31 22 1 –
Vomiting 13 17 10 2 1
Diarrhea 11 15 7 4 –
Liver
Elevated liver enzymes 12 15 11 1 –
Other
Fatigue 4 5 4 – –
Weight loss 2 3 2 – –
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effects were common and were documented in 57 % of
the patients, they were usually mild and transient. Only
two patients stopped DTIC due to side effects. Dose ad-
justments were necessary in only three other cases. Not-
ably, in contrast to former studies our patients did not
experience grade 3 and 4 hematotoxicity. For instance,
Ramanathan et al. reported 30 % grade 3 and 4 toxicities
including 10 % grade 4 hematotoxicity [6] probably due
to the use of a higher dose of DTIC of 850 mg/m2.
Temozolomide is closely related to dacarbazine and
shares the same active metabolite. It is available in an
oral formulation, crosses the blood–brain barrier and
has recently been advocated as effective, well tolerated
and convenient chemotherapy for patients with NEN.
Temozolomide as a single therapeutic agent has been
studied by Maire and coworkers in 21 mostly pretreated
NEN patients [26]. They showed a relative low response
rate of 5 %, but a disease stabilization in 81 %. The
Uppsala group reported comparable results using temo-
zolomide monotherapy in patients with advanced NEN
(n = 36) achieving a response rate of 14 % and a stable
disease rate of 53 % [25]. Although comparisons be-
tween these studies are always very limited due to the
fact that patient characteristics differ significantly, in
our study DTIC does not appear to be inferior to the re-
sults reported for temozolomide monotherapy.
In combination with capecitabine, temozolomide has
shown a high response rate of 70 % in one small retro-
spective study of pancreatic NEN [3] suggesting syner-
gistic effects between both drugs. However, all the
patients in this study were chemotherapy naïve. Temo-
zolomide in combination with capecitabine therefore
seems to be a promising alternative to streptozocin
based therapy of metastasized pancreatic NENs. A ran-
domized prospective trial comparing both regimens is
needed to determine which is the most effective regimen
that should be used in first line treatment. Most temozo-
lomide +/− capecitabine studies reported more severe
side effects, in particular grade 3 hematologic toxicity
(10–15 %) than observed in our trial. Authors have also
reported a considerable incidence of opportunistic infec-
tions (10 %) related to this therapy which has rarely been
reported in DTIC monotherapy and was not observed in
our series [27]. Although DTIC has the disadvantage of
an intravenous application route, patient discomfort is
negligible, since treatment comprises a single infusion
every 4 weeks in an outpatient setting. In direct compari-
son of the two regimens, the cost of the drug may be of
relevance, since the price of a standard 5 day temozolo-
mide course in Germany is approximately 14 times higher
than the price of a single DTIC infusion. Since dacarba-
zine in our experience shows similar efficacy as temozolo-
mide, we have just started to evaluate the efficacy and
safety of combining dacarbazine with capecitabine.
Temozolomide has as well been used as second line
chemotherapy in a small series of G3 NEN and demon-
strated a response rate of 33 % [28]. Response rates were
higher in tumors with Ki 67 < 60 % and in patients with
positive somatostatin receptor imaging, indicating that
these tumours had a higher degree of differentiation. Inter-
estingly, adding capecitabine to temozolomide brought no
additional benefit in this small series. In the same way,
Olsen et al. found a response rate of 38 % in 25 patients
with NECs using temozolomide alone [29]. Temozolomide
may therefore be a therapeutic alternative in NEC G3 tu-
mors with a Ki 67 index between 21 and 60 % which are
not as aggressive as undifferentiated small cell G3 neuro-
endocrine cancers and often do not respond to standard
cisplatin/etoposide therapy.
Apart from conventional chemotherapy the use of
everolimus and sunitinib has provided novel and effective
treatments for pNETs. However, the response rates
achieved with these new agents overall are lower than
with conventional chemotherapy and side effects can be
considerable. The combination of temozolomide and
everolimus has recently shown to be active in pNETs, with
a response rate of 40 %, which is not superior to the re-
sults obtained with temozolomide plus capecitabine [30].
First promising results have as well been reported for
the combination of temozolomide/capecitabine and pep-
tide receptor radiotherapy (PRRT) in pNET with re-
sponse rates of 82 % [31].
Thus, conventional chemotherapy with drugs such as
dacarbazine, temozolomide and/or capecitabine shows
strong activity in pNET and should be included in
current treatment algorithms. They may also represent
the backbone for trials of novel combination therapies.
Conclusions
In summary, treatment with low dose (650 mg/m2) dacar-
bazine monotherapy demonstrated efficacy in progressive
well differentiated NEN patients. Toxicity rates are con-
siderably lower than those observed with high dose DTIC
and combination treatments including streptozocin based
regimens. Thus, low dose dacarbazine may be a thera-
peutic alternative for patients with well differentiated pan-
creatic NETs, in particular as second-line therapy. Future
prospective randomized trials are necessary to further
evaluate its role in patients with progressive well-
differentiated NENs of pancreatic and lung origin.
Additional file
Additional file 1: Table S1. Summary of pretreatments of our patient
cohort: 25 patients received one prior treatment, 33 patients received
two prior treatments, six patients received three prior treatments, two
patients four prior treatments and one patient five prior treatments
before starting dacarbazine. (DOCX 18 kb)
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